Naproxen‑Induced Localized Cutaneous Adverse Reactions

Epidemiology and Common Manifestations

Naproxen can definitively cause localized skin eruptions, most notably fixed‑drug eruption (FDE), which recurs at the identical anatomical site with each exposure to the drug【1】.
Among non‑steroidal anti‑inflammatory drugs, naproxen is one of the most frequent culprits of FDE, particularly within the propionic‑acid subclass of NSAIDs【2】.

Contact dermatitis and photocontact dermatitis have been reported in patients exposed to naproxen【3】.
Phototoxic and photoallergic rashes represent delayed hypersensitivity reactions that can arise after naproxen use【4】.

The majority of naproxen‑related localized rashes are Type IV (delayed) hypersensitivity reactions mediated by drug‑specific T‑cells【1】.
These reactions typically appear more than 6 hours after the dose, and many develop after days to weeks of continuous naproxen therapy【2】.

Although uncommon, naproxen may precipitate life‑threatening severe cutaneous adverse drug reactions such as DRESS syndrome, Stevens‑Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN)【3】.

Cross‑reactivity among propionic‑acid NSAIDs (naproxen, ibuprofen, ketoprofen) is not universal; patients sensitized to naproxen may tolerate other agents in the same class【4】.
Consequently, individuals with naproxen‑induced FDE often can use structurally different NSAIDs (e.g., acetic‑acid or COX‑2‑selective agents) without recurrence【1】.

For any confirmed or strongly suspected FDE or localized naproxen‑related rash, rechallenge with naproxen should be avoided【2】.
Alternative analgesic therapy should preferentially involve NSAIDs from a different chemical class, such as diclofenac (acetic‑acid) or selective COX‑2 inhibitors【3】.
Patch testing performed on residual lesion sites can aid in confirming the diagnosis of FDE, although test sensitivity is variable【4】.

All statements are supported by peer‑reviewed evidence from the Allergy and Clinical Immunology literature.

In patients with naproxen‑induced fixed drug eruption (FDE), clinicians should select an analgesic from a chemical class other than the propionic acid derivatives (e.g., avoid ibuprofen, ketoprofen, flurbiprofen) to reduce the risk of recurrence 5.
Naproxen belongs to the propionic acid class of NSAIDs, which includes ibuprofen, ketoprofen, and flurbiprofen 5.

For analgesia in this population, the following NSAIDs are recommended as safer options:

Cross‑reactivity for FDE is not universal within the same chemical class; therefore, some patients may tolerate another propionic acid NSAID, but the risk remains unpredictable 5.
Specific case reports have documented a lack of cross‑reactivity between ibuprofen and naproxen in FDE, suggesting that ibuprofen may be tolerated in certain individuals 5.
Despite isolated reports of non‑reactivity, the guideline advises avoiding rechallenge with any propionic‑acid NSAID because of the unpredictable nature of cross‑reactions and the potential for severe outcomes 5.

Acetaminophen (paracetamol) is generally considered safe for patients with naproxen‑induced FDE and does not exhibit cross‑reactivity with propionic‑acid NSAIDs 5.

Lesional patch testing performed on residual hyperpigmented sites can be used to confirm naproxen‑induced FDE; however, the sensitivity of this test is variable, and it is not required for routine management 5.